"Dihydroergotamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.
| Descriptor ID |
D004087
|
| MeSH Number(s) |
D03.132.327.412.225 D03.633.400.562.300
|
| Concept/Terms |
DHE-45- DHE-45
- DHE 45
- DHE45
- D.H.E. 45
Dihydroergotamine Mesylate- Dihydroergotamine Mesylate
- Mesylate, Dihydroergotamine
- Dihydroergotamine Methanesulfonate
- Methanesulfonate, Dihydroergotamine
Migranal- Migranal
- Dihydergot
- Dihydroergotamine-Sandoz
- Dihydroergotamine Sandoz
|
Below are MeSH descriptors whose meaning is more general than "Dihydroergotamine".
Below are MeSH descriptors whose meaning is more specific than "Dihydroergotamine".
This graph shows the total number of publications written about "Dihydroergotamine" by people in this website by year, and whether "Dihydroergotamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dihydroergotamine" by people in Profiles.
-
Tepper SJ, Ailani J, Ray S, Hirman J, Shrewsbury SB, Aurora SK. Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure. J Headache Pain. 2022 Nov 22; 23(1):148.
-
Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013 Sep; 53 Suppl 2:43-53.
-
Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, Silberstein SD. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012 Jan; 52(1):37-47.
-
Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011 Oct; 86(10):948-55.
-
Whyte CA, Stillman MJ, Tepper SJ. Dihydroergotamine and its use in migraine with posterior fossa symptoms. Headache. 2010 Oct; 50(9):1419-23.
-
Lovell BV, Marmura MJ. New therapeutic developments in chronic migraine. Curr Opin Neurol. 2010 Jun; 23(3):254-8.
-
Silberstein SD. Meeting acute migraine treatment needs through novel treatment formulations. Neurotherapeutics. 2010 Apr; 7(2):153-8.
-
Halker R, Vargas B, Dodick DW. Cluster headache: diagnosis and treatment. Semin Neurol. 2010 Apr; 30(2):175-85.
-
Nahas SJ, Silberstein SD. Triptans: actions and reactions. Headache. 2008 Apr; 48(4):611-3.
-
Silberstein SD, Young WB, Hopkins MM, Gebeline-Myers C, Bradley KC. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache. 2007 Jun; 47(6):878-85.